Eli Lilly Launches Mounjaro in India

Eli Lilly and Company launched its diabetes and obesity management drug, Mounjaro (tirzepatide), in India on March 20, 2025, after receiving marketing authorization from the India — Central Drugs Standard Control Organisation. Mounjaro is a first-of-its-kind treatment that activates both GIP and GLP-1 hormone receptors, demonstrating significant weight loss and improved glycemic control in clinical trials. The drug is priced competitively in India, with monthly costs ranging from ₹14,000 to ₹17,500, significantly lower than in the US. This launch addresses the growing public health challenge of obesity and Type 2 diabetes in India, where approximately 101 million people live with diabetes and nearly 100 million are affected by obesity. While Eli Lilly and Company gains a first-mover advantage, it faces impending competition from generic versions of semaglutide from Indian players like Mankind Pharma, Abbott Laboratories, and Abbott Laboratories, as well as existing market presence from Novo Nordisk's Rybelsus. Experts like Dr. Nikhil Tandon and Dr. Ambrish Mithal emphasize the need for responsible prescribing and medical supervision to prevent misuse, despite the drug's promising efficacy. Winslow Tucker, President and General Manager of Lilly India, reiterated the company's commitment to collaborating with the government and industry to promote awareness and improve disease management.